Pharmaceutical - Johnson & Johnson


Current filters:

Johnson & Johnson

Popular Filters

176 to 200 of 245 results

Johnson & Johnson to set up innovation centers to accelerate partnering


US health care giant Johnson & Johnson (NYSE: JNJ) yesterday said it plans to establish four regional…

Johnson & JohnsonLicensingMergers & AcquisitionsPharmaceuticalResearch

Senior appointments at Teva and Johnson & Johnson


Israel's Teva Pharmaceutical Industries (NYSE: TEVA) has announced the appointment of Itzhak Krinsky…

GenericsJohnson & JohnsonManagementPharmaceuticalTeva Pharmaceutical Industries

Janssen responds to FDA's Xarelto CRL; resubmits sNDA


Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Research & Development, German drug major Bayer's (BAYN:…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

ImmuNext partners with Janssen in up to $150 million cancer discover deal


Closely-held USA-based ImmuNext has entered into an agreement with Janssen Biotech, a unit of US health…

ImmuNextJanssen BiotechJohnson & JohnsonLicensingOncologyPharmaceuticalResearch

Janssen-Cilag files for EU approval of bedaquiline in MDR-TB


Johnson & Johnson (NYSE: JNJ) Belgium-based subsidiary Janssen-Cilag International submitted a Marketing…

Antibiotics and Infectious diseasesbedaquilinedelamanidEuropeJanssen-CilagJohnson & JohnsonOtsukaPharmaceuticalRegulation

Genmab leaps on $1.1 billion daratumumab deal with Janssen


Denmark's Genmab A/S (OMX: GEN) saw its shares leap 20% to 81 Danish kroner in morning trading yesterday,…

BiotechnologydaratumumabFinancialGenmabHuMax-CD38JanssenJohnson & JohnsonLicensingOncologyPharmaceutical

Janssen to pay $181 million in Risperdal settlement


US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Pharmaceuticals yesterday announced a settlement…

JanssenJohnson & JohnsonLegalMarkets & MarketingNorth AmericaPharmaceuticalRisperdal

FDA OKs new indication for Janssen's Nucynta and fast tracks Zytiga sNDA


There were two pieces of good news for US health care giant Johnson & Johnson (NYSE: JNJ) subsidiaries…

BiotechnologyJanssenJohnson & JohnsonNeurologicalNorth AmericaNucyntaOncologyPharmaceuticalRegulationZytiga

First-line multiple myeloma patient share in Europe is variable by country


Despite the considerable heterogeneity across different European countries, surveyed hematologist-oncologists…

AlkeranBiotechnologyCelgeneGlaxoSmithKlineHealthcareJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalThalomidVelcade

US surveyed PCPs and pain specialists experienced reimbursement restrictions for Janssen's Nucynta ER


The majority of US surveyed primary care physicians (PCPs) and pain specialists indicate that they have…

JanssenJohnson & JohnsonMarkets & MarketingNeurologicalNorth AmericaNucyntaPfizerPharmaceuticalPricingtanezumab

Bayer and J&J's Xarelto aids survival after heart attack


A major subgroup analysis from the ATLAS ACS 2-TIMI 51 study of 7,817 patients with acute coronary syndrome…

BayerCardio-vascularJohnson & JohnsonPharmaceuticalResearchXarelto

Janssen initiates Ph III study of sirukumab, being developed with GSK


Janssen Biologics (Ireland), part of US health care giant Johnson & Johnson (NYSE: JNJ), has initiated…

Anti-Arthritics/RheumaticsGlaxoSmithKlineJanssenJohnson & JohnsonPharmaceuticalResearchsirukumab

Pharmacyclics gets second $50 million milestone from Janssen


California, USA-based Pharmacyclics (Nasdaq: PCYC) announced yesterday that the SPARK (MCL2001) clinical…

BiotechnologyFinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Scottish regulator backs restricted NHS use of Janssen's Zytiga; negative on BioMarin's Firdapse


The Scottish Medicines Consortium (SMC) announced yesterday that it has accepted Johnson & Johnson (NYSE:…

BioMarin PharmaceuticalEuropeFirdapseJanssenJohnson & JohnsonOncologyPharmaceuticalPricingRare diseasesRegulationZytiga

Crucell and Scripps Research discover broad-spectrum antibodies against influenza B


In what is described as a landmark discovery, researchers from Crucell Holland, which became wholly-owned…

Anti-viralsBiotechnologyCrucellJohnson & JohnsonPharmaceuticalResearchVaccines

J&J and Pfizer drop bapineuzumab development for Alzheimer's


There was disappointing - though not really unexpected - news yesterday for US health care giant Johnson…

bapineuzumabElanJanssenJohnson & JohnsonNeurologicalPfizerPharmaceuticalResearch

Pharmacyclics gets $50 milestone from J&J on ibrutinib progress


California, USA-based Pharmacyclics (Nasdaq: PCYC) says it that enrolment of the fifth patient in the…

FinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Pfizer and Janssen's bapineuzumab fails to meet one Ph III study endpoints for Alzheimer's


US drugs behemoth Pfizer (NYSE: PFE) revealed yesterday that the co-primary clinical endpoints, change…

bapineuzumabJanssenJohnson & JohnsonNeurologicalPfizerPharmaceuticalResearch

Johnson & Johnson 2nd-qtr earnings slump on charges and currencies


US health care giant Johnson & Johnson (NYSE: JNJ) yesterday announced second-quarter 2012 financial…

FinancialJohnson & JohnsonPharmaceutical

Genmab in collaboration with Janssen for DuoBody platform


Denmark-based Genmab A/S (OMX: GEN) says it has entered into a collaboration with Janssen Biotech, a…

BiotechnologyDuoBodyGenmabJanssen BiotechJohnson & JohnsonLicensingNovartisPharmaceutical

J&J'S rilpivirine also proven for combination HIV product, says IQWiG


Since the start of 2012, a new drug - rilpivirine from US health care giant Johnson & Johnson (NYSE:…

Anti-viralsEuropeEvipleraJohnson & JohnsonPharmaceuticalPricingRegulationrilpivirine

US priority review for two Xarelto sNDAs; one dropped


The US Food and Drug Administration has assigned a priority review designation to the supplemental New…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

176 to 200 of 245 results

Back to top